And Then There Was One: HCV Elimination in the Coinfected Population
“The treatment of the hepatitis C virus (HCV) has evolved considerably in the past 15 years. Second-generation direct-acting antivirals entered the market in late 2014. Today we have well-tolerated, short-course (generally 8-12 weeks), pangenotypic options with greater than 95% efficacy to achieve cure or sustained virologic response (SVR). In the World Health Organization’s (WHO) most recent global health sector strategies for 2022 to 2030, it is estimated that the treatment of HCV worldwide increased 10-fold since 2015.”
Insights from patient who cleared hepatitis C could lead to vaccine
“By studying individuals who spontaneously clear hepatitis C infections, a team of researchers has identified viable vaccine targets for a disease that infects 70 million worldwide with case numbers increasing every year.”
Over 30 years, big fall in HIV among people who inject drugs in Baltimore, but hepatitis C remains high
“Despite less injecting drug use, increased use of harm reduction services, and significant progress in reducing HIV infections, there has been a resurgence of hepatitis C among people who inject drugs in recent years in Baltimore, especially among people under the age of 40. This research, tracking changes over the past three decades, was presented by Eshan Patel to the recent Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver.”
State sues El Dorado county over needle exchange bans
“PLACERVILLE, Calif. – As part of an ongoing dispute between some county officials and the Sierra Harm Reduction Coalition, a nonprofit that distributes clean needles, Narcan and offers other services, Placerville’s City Council and the El Dorado County Board of Supervisors both recently passed bans on the operation of needle exchange programs. Following on the heels of the latter of the two bans, passed by City Council in late February, the California Department of Public Health filed a lawsuit against the two governing bodies and their elected officials.”
‘Time for Five’ coalition launches global petition targeting medical test maker Cepheid and parent corporation Danaher
“Washington, DC, 22 March 2024 — Ahead of World Tuberculosis (TB) Day, the international medical humanitarian organization Doctors Without Borders/Medecins Sans Frontieres (MSF) protested alongside other global health activists outside the headquarters of US corporation Danaher, which owns diagnostics maker Cepheid, demanding they drop the price to US$5 for all their ‘GeneXpert’ medical tests that they sell in low- and middle-income countries, for diseases such as tuberculosis (TB), HIV, hepatitis, sexually transmitted infections (STIs) and Ebola. Testing is the first step to getting someone who is sick on the treatment they need and preventing further spread of infectious diseases.”
US centers get $2.1M to help hepatitis patients find doctors
“The Center for Disease Analysis (CDA) Foundation has granted $2.1 million in funding to 14 U.S. organizations to help diagnosed but untreated hepatitis B and C patients find doctors. The funds come from the foundation’s Relink grant program, which is supported by an $8-million grant from Gilead Sciences. Gilead markets several hepatitis therapies. The CDA Foundation plans to distribute three more rounds of Relink grants by 2025.”
